Compounds > platencin
Page last updated: 2024-11-12

platencin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

platencin: inhibits both FabF and FabH; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

platencin : A monocarboxylic acid amide obtained by the formal condensation of the amino group of 3-amino-2,4-dihydroxybenzoic acid with the carboxy group of the polycyclic cage component. It is an antibiotic isolated from Streptomyces platensis and exhibits inhibitory activity against fatty acid synthase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16745128
CHEMBL ID1092943
CHEBI ID68241
MeSH IDM0510515

Synonyms (19)

Synonym
platencin
2,4-dihydroxy-3-({3-[(2s,4as,8s,8ar)-8-methyl-3-methylidene-7-oxo-1,3,4,7,8,8a-hexahydro-2h-2,4a-ethanonaphthalen-8-yl]propanoyl}amino)benzoic acid
N32 ,
CHEMBL1092943
chebi:68241 ,
2,4-dihydroxy-3-({3-[(4as,8s,8ar)-8-methyl-3-methylidene-7-oxo-1,3,4,7,8,8a-hexahydro-2h-2,4a-ethanonaphthalen-8-yl]propanoyl}amino)benzoic acid
869898-86-2
unii-xk356w8oob
Q27136732
2,4-dihydroxy-3-[3-[(1s,5s,6r,8s)-5-methyl-9-methylidene-4-oxo-5-tricyclo[6.2.2.01,6]dodec-2-enyl]propanoylamino]benzoic acid
XK356W8OOB ,
benzoic acid, 3-((3-((2s,4as,8s,8ar)-1,3,4,7,8,8a-hexahydro-8-methyl-3-methylene-7-oxo-2h-2,4a-ethanonaphthalen-8-yl)-1-oxopropyl)amino)-2,4-dihydroxy-
(-)-platencin
3-((3-((2s,4as,8s,8ar)-1,3,4,7,8,8a-hexahydro-8-methyl-3-methylene-7-oxo-2h-2,4a-ethanonaphthalen-8-yl)-1-oxopropyl)amino)-2,4-dihydroxybenzoic acid
platencin [mi]
HY-118512
CS-0066239
AKOS040756240
bdbm50601421

Research Excerpts

Overview

Platencin is a novel antibiotic which is active against multiresistant pathogens.

ExcerptReferenceRelevance
"Platencin is a novel antibiotic which is active against multiresistant pathogens. "( Syntheses and antibacterial properties of iso-platencin, Cl-iso-platencin and Cl-platencin: identification of a new lead structure.
Gollner, A; Mulzer, J; Tiefenbacher, K, 2010)		2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 2.3.1.85 (fatty acid synthase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
cyclic ketone
polycyclic cageA polycyclic compound having the shape of a cage.
dihydroxybenzoic acidAny member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-oxoacyl-[acyl-carrier-protein] synthase 2Staphylococcus aureusIC50 (µMol)4.58004.58004.58004.5800AID1894106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (114)

Assay IDTitleYearJournalArticle
AID318375Inhibition of Staphylococcus aureus FabH by direct binding assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1894109Antibacterial activity against Staphylococcus aureus MRSA assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID1744564Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID475490Antibacterial activity against wild type Escherichia coli MB2884 after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1430488Drug uptake in C57Bl/6 mouse lung at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID475487Inhibition of Staphylococcus aureus FAS2 assessed as 2-[14C]malonyl-CoA incorporation after 90 mins by scintillation counting2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1744562Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318351Antibacterial activity against methicillin-sensitive Staphylococcus aureus2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1894113Antibacterial activity against Streptococcus pneumoniae assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID475492Antifungal activity against Candida albicans after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1744556Inhibition of Staphylococcus aureus FabB/FabF2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430475Observed clearance in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430487Drug uptake in C57Bl/6 mouse liver at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430465Cmax in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430514In vivo stability in C57Bl/6 mouse muscle assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430486Drug uptake in C57Bl/6 mouse plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID595207Antibacterial activity against Haemophilus influenzae at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID475493Cytotoxicity against human HeLa cells by MTT assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1744572Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as stoichiometry ratio measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744569Binding affinity to His6-tagged Staphylococcus aureus FabF expressed in Escherichia coli BL21 (DE3) assessed as decrease in melting temperature at 10 uM by SYPRO orange based differential scanning fluorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1350036Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 7 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1894111Antibacterial activity against Linezolid-resistant Staphylococcus aureus MRSA assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID1430493Ratio of drug level in C57Bl/6 mouse lung to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744573Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318357Antibacterial activity against macrolide-resistant Enterococcus faecalis2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1744563Antibacterial activity against methicillin sensitive Staphylococcus aureus assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1350031Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 2 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430483Oral bioavailability in C57Bl/6 mouse at 10 mg/kg administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1350037Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 8 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430476Volume of distribution in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID595205Antibacterial activity against Enterococcus faecium at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID1430466Cmax in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1412974Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID318369Inhibition of fatty acid synthesis in Streptococcus pneumoniae in whole cell activity assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1430513In vivo stability in C57Bl/6 mouse lung assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430524In vivo stability in C57Bl/6 mouse brain assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318382Inhibition of Staphylococcus aureus FabF assessed as reduced accumulation of acetoacetyl-ACP by FabF/FabH PAGE elongation assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1430515In vivo stability in C57Bl/6 mouse adipose tissue assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744578Antibacterial activity against methicillin resistant Staphylococcus aureus infected in C57BL/6J mouse model of peritonitis assessed as bacterial load in kidney at 10 mg/kg, ip administered at 1 and 5 hrs post infection2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430495Ratio of drug level in C57Bl/6 mouse muscle to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318374Inhibition of Staphylococcus aureus FabF by direct binding assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1350029Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430523In vivo stability in C57Bl/6 mouse urine assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318381Inhibition of Staphylococcus aureus FabH assessed as reduced accumulation of long chain beta-ketoacyl-ACP by FabF/FabH PAGE elongation assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID595201Antibacterial activity against Streptococcus pneumoniae at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID431289Inhibition of Escherichia coli FabF C163F2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Isolation, enzyme-bound structure and antibacterial activity of platencin A1 from Streptomyces platensis.
AID318368Inhibition of fatty acid synthesis in Staphylococcus aureus in whole cell activity assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1350032Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 3 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID318362Antibacterial activity against Staphylococcus aureus expressing antisense fabF assessed as drug level causing >5 mm zone of inhibition after 18 hrs by agar diffusion two plate differential sensitivity antisense assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1894112Antibacterial activity against Vancomycin-resistant Staphylococcus aureus VISA assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID595206Antibacterial activity against Escherichia coli at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID1430492Ratio of drug level in C57Bl/6 mouse liver to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318363Cytotoxicity against human HeLa cells by MTT assay2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID475484Antibacterial activity against Staphylococcus aureus Lin after 20 hrs by NCCLS method in presence of 50 % serum2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID318358Antibacterial activity against vancomycin-resistant Enterococcus faecium2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1430461Elimination half life in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430460Elimination half life in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318366Antibacterial activity against methicillin-sensitive Staphylococcus aureus infected mouse kidney assessed as log reduction of bacterial count at 150 ug/hr after 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID475488Antibacterial activity against Bacillus subtilis MB964 after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1894107Inhibition of Staphylococcus aureus FabH2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID1430491Drug uptake in C57Bl/6 mouse adipose tissue at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID475483Antibacterial activity against Enterococcus faecalis CL8516 after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1744574Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as change in entropy measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318361Antibacterial activity against efflux negative-tolC mutant containing Escherichia coli2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1744555Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744579Antibacterial activity against methicillin resistant Staphylococcus aureus infected in C57BL/6J mouse model of peritonitis assessed as mouse survival when infected with 2.5x10^7 CFU bacteria at 10 mg/kg, ip administered at 1 and 5 hrs post infection2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430470AUC (0 to 8 hrs) in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID431279Inhibition of FAS2 in Staphylococcus aureus assessed as inhibition of fatty acid synthesis by scintillation counting2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Isolation, enzyme-bound structure and antibacterial activity of platencin A1 from Streptomyces platensis.
AID318354Antibacterial activity against methicillin and macrolide-resistant Staphylococcus aureus2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1744557Inhibition of Staphylococcus aureus FabH2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1412976Antibacterial activity against methicillin-resistant Staphylococcus aureus after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID1430520In vivo stability in C57Bl/6 mouse plasma assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1350039Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 10 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID595203Antibacterial activity against Staphylococcus aureus at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID318364Toxicity in human RBC assessed as drug level causing hemolysis2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1894106Inhibition of Staphylococcus aureus FabF2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID431282Antibacterial activity against Staphylococcus aureus assessed as minimum concentration required to differential zone of clearance between antisense plate compared to control2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Isolation, enzyme-bound structure and antibacterial activity of platencin A1 from Streptomyces platensis.
AID1744568Antibacterial activity against Escherichia coli harboring delta tolC mutant assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318365Antifungal activity against Candida albicans2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1350035Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 6 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1412975Antibacterial activity against methicillin-sensitive Staphylococcus aureus after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID1350028Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 11 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1744571Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as binding constant measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318367Toxicity in methicillin-sensitive Staphylococcus aureus infected mouse model at 150 ug/hr after 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1744576Antibacterial activity against methicillin resistant Staphylococcus aureus infected in C57BL/6J mouse model of peritonitis assessed as mouse survival at 10 mg/kg, ip administered at 1 and 5 hrs post infection2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID475486Antibacterial activity against Staphylococcus aureus expressing FabF antisense plasmid S1-1941 assessed as minimum concentration required to produce differential zone of clearance after 18 hrs by antisense two-plate differential sensitivity cellular assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1350034Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 5 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1744566Inhibition of Staphylococcus aureus FabH A81V mutant assessed as bacterial growth inhibition measured after 18 hrs by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430521In vivo stability in C57Bl/6 mouse liver assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1350038Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 9 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID475491Antibacterial activity against envelope disrupted Escherichia coli MB5746 after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1744565Inhibition of Staphylococcus aureus FabH A81V/A111T mutant assessed as bacterial growth inhibition measured after 18 hrs by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744575Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed Gibbs free energy change measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744570Binding affinity to His6-tagged Escherichia coli FabH expressed in Escherichia coli BL21 (DE3) assessed as decrease in melting temperature at 10 uM by SYPRO orange based differential scanning fluorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID475485Antibacterial activity against Staphylococcus aureus Smith after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID1894108Antibacterial activity against Staphylococcus aureus MSSA assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
AID318355Antibacterial activity against methicillin and linezolid-resistant Staphylococcus aureus2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1430471AUC (0 to 8 hrs) in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430494Ratio of drug level in C57Bl/6 mouse kidney to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID318356Antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1350030Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 1 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID318352Antibacterial activity against Staphylococcus aureus in presence of serum2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID318353Antibacterial activity against methicillin-resistant Staphylococcus aureus2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1350033Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 4 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID475489Antibacterial activity against Haemophilus influenzae MSD2261 after 20 hrs by NCCLS method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis.
AID318359Antibacterial activity against Streptococcus pneumoniae2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID318360Antibacterial activity against wild type Escherichia coli2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID595204Antibacterial activity against Enterococcus faecalis at 64 ug/ml after 20 hrs2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Platensimycin and platencin congeners from Streptomyces platensis.
AID1744567Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth measured after 18 hrs in presence of 10% human serum by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID318380Inhibition of Staphylococcus aureus FabD assessed as reduced malonyl-ACP levels2007Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 104, Issue:18
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
AID1430489Drug uptake in C57Bl/6 mouse kidney at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430522In vivo stability in C57Bl/6 mouse kidney assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430490Drug uptake in C57Bl/6 mouse muscle at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1894110Antibacterial activity against Macrolide-resistant Staphylococcus aureus MRSA assessed as bacterial growth inhibition2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Chemical Highlights Supporting the Role of Lipid A in Efficient Biological Adaptation of Gram-Negative Bacteria to External Stresses.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (30.77)29.6817
2010's40 (61.54)24.3611
2020's5 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.00 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.1510amino-acid anion
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.0510halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		2.110azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		7.1510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.0310C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.1510aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.3110beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
1,4-cyclohexanedimethanol
1,4-cyclohexanedimethanol: used as a monomer in the production of polyester resins; RN given refers to cpd with specified locants for dimethanol groups		2.0510
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		7.78340adamantanes;
polycyclic alkane
thiazoles
[no description available]		3.31101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
2-piperidone
2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.		3.3110delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
perillaldehyde
perillaldehyde: from oil of Perillae herba; has neuropharmacological actions; RN given refers to cpd without isomeric designation; structure in Merck Index, 9th ed, #6956. perillyl aldehyde : An aldehyde that is cyclohex-1-ene-1-carbaldehyde substituted by a prop-1-en-2-yl group at position 4.		2.0510aldehyde;
olefinic compound		human metabolite;
mouse metabolite;
volatile oil component
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		2.0510metal allergen;
nickel group element atom;
platinum group metal atom
1,4-dioxane
1,4-dioxane: dehydrating agent; polar solvent miscible both with water & most organic solvents. dioxane : Any member of the class of dioxanes that is a cyclohexane in which two carbon atoms are replaced by oxygen atoms.. 1,4-dioxane : A dioxane with oxygen atoms at positions 1 and 4.		2.110dioxane;
volatile organic compound		carcinogenic agent;
metabolite;
NMR chemical shift reference compound;
non-polar solvent
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.0810D-glucopyranoseepitope;
mouse metabolite
teleocidin b-4
teleocidins: structure; RN given refers to teleocidin		3.3510
ws 9659 a
lavanducyanin: isolated from Steptomyces sp. CL190& from Streptomyces sp No.9659		3.3510
linezolid
[no description available]		3.0440acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
geranylgeranyl pyrophosphate
geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.		2.0710geranylgeranyl diphosphatemouse metabolite
iridoids
Iridoids: A type of MONOTERPENES, derived from geraniol. They have the general form of cyclopentanopyran, but in some cases, one of the rings is broken as in the case of secoiridoid. They are different from the similarly named iridals (TRITERPENES).		3.3510
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0310antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		3.4110epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		2.8530chalcogen;
nonmetal atom		macronutrient
platensimycin
platensimycin: has antidiabetic and antisteatotic activities; a pentacyclic ketolide (structurally similar to adamantane) connected by an amide bond to 3-amino-2,4-dihydroxybenzoic acid; inhibits cellular lipid biosynthesis; discovered while screening compounds from Streptomyces platensis bacteria in a South African soil sample with S. aureus bacteria deficient in FabF protein; structure in first source. platensimycin : A monocarboxylic acid amide obtained by the formal condensation of the amino group of 3-amino-2,4-dihydroxybenzoic acid with the carboxy group of the oxatetracyclic cage component. It is an antibiotic isolated from Streptomyces platensis and exhibits inhibitory activity against fatty acid synthase.		7.82350aromatic amide;
cyclic ether;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
dc 107
leinamycin: a thiazole containing macrolide characterized by an unusual 1,3-dioxo-1,2-dithiolane moiety that is spiro fused to an 18 member macrolactam ring; isolated from Streptomyces; MF C22-H26-N2-O6-S3; possible DNA alkylator; the leinamycin biosynthetic gene cluster from Streptomyces atroolivaceus S-140 consists of two polyketide synthases genes		3.3110dithiolanes
polymyxin b(1)
[no description available]		2.3110
chir 090
CHIR 090: structure in first source. CHIR-090 : An L-threonine derivative obtained by formal condensation of the carboxy group of 4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)benzoic acid with the amino group of N-hydroxy-L-threoninamide.		3.4110acetylenic compound;
benzamides;
hydroxamic acid;
L-threonine derivative;
morpholines		antimicrobial agent;
EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor;
lipopolysaccharide biosynthesis inhibitor
isomigrastatin
isomigrastatin: isolated from Streptomyces platensis; structure in first source		3.3110macrolide
ConditionIndicatedRelationship StrengthStudiesTrials
Brucella Infection
[description not available]		02.2510
Brucellosis
Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.		02.2510
Infectious Diseases
[description not available]		03.0610
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		03.0610
Bacterial Infections, Gram-Positive
[description not available]		02.9810
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.9810
Bacterial Disease
[description not available]		02.0610
Bacterial Infections
Infections by bacteria, general or unspecified.		02.0610